Our People

Torsten founded Proteros based on the belief that structural biology services would become a key market requirement in the future of industrial Drug Discovery.

 

Torsten set up the company based on a McKinsey & Co awarded business plan and the experience of his PhD thesis in the lab of Nobel prize winner Prof. R. Huber at the Max Planck Institute of Biochemistry, Munich as well as at Bayer AG. He set up the company structure, including high performance teams, a supervisory board and involvement of Prof. Huber as a co-founder and scientific advisor. He continues to manage the financing of the growth of the company in all stages and developed the business in Europe, US and Japan and made Proteros a renowned market leader in its segment, awarded as one of Bavaria’s best innovative growth companies. 

Joseph Van Tiem serves as Chief Financial Officer at Proteros, bringing extensive finance leadership experience and a strong understanding of the life sciences industry. Joseph plays a key role in supporting the company’s strategic development and continued growth. He is responsible for further strengthening the Finance function as a strategic business partner, providing financial insights and transparency to guide business decisions, support operational excellence and enable sustainable growth. Working closely with the Commercial and Operations teams, he helps ensure that financial strategy and business priorities are aligned as Proteros continues to expand and evolve. A US-trained finance executive and Certified Public Accountant (CPA), he combines international financial expertise with a strategic, business-oriented perspective. Prior to joining Proteros, Joseph held senior finance leadership positions at Evotec, where he was responsible for financial planning and analysis, accounting and controlling, supporting business performance and strategic decision-making across a global organisation.

LinkedIn

Ryan Brady leads Proteros’ global commercial strategy — spanning business development, strategic partnerships, client engagement, and marketing — as we continue our mission to support our clients to reach the right results and accelerate their overall research timelines, helping them to open the door to lead optimization and clinical programs. Ryan brings over 20 years of experience with a proven track record in the key areas of business development and strategic partnerships in our industry. Prior to joining Proteros, he held the position as Head of Global Discovery Business Development at Evotec Throughout his career, Ryan has consistently demonstrated a passion for connecting cutting-edge science with impactful partnerships with customers — building bridges between innovation and execution to help clients advance tomorrow’s medicines faster and smarter.

LinkedIn

Eric P. Pâques is Non-Executive Chairman of the Supervisory Board of Proteros Biostructures GmbH (Munich, Germany) since 2014, chairman of the Board of Directors of Novadip Biosciences (Belgium) and Board member of Epics Therapeutics (Belgium) and of PL Bioscience (Germany) as well as of several academic and charity organizations. He was Independent Director of INC Research Inc., later Syneos Health, (USA), and Vice-Chairman of the Supervisory Board of the Grünenthal Group (Germany). He served more than 35 years in management positions in the pharmaceutical industry, thereof 20 years as General Manager / CEO of the Grünenthal Group. He is professor at the RWTH-Aachen University (Germany) and holds a Master degree and a PhD in Chemistry (University of Louvain, Belgium).

LinkedIn